Evotec SE Makes Strategic Equity Investment in IMIDomics, Inc.

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

Avista Capital Partners Invests in eMolecules

March 25, 2021

Healthcare Services

Avista Capital Partners has signed a definitive agreement to invest in eMolecules, a San Diego–based e-procurement and marketplace platform for high-value chemicals and bioreagents used in drug discovery. Financial terms were not disclosed; Avista said the investment will support eMolecules' growth and expansion into additional biopharma and academic customers.

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

Pharmaceuticals

Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.

VeriSIM Life Acquires Molomics Biotech

May 11, 2022

Biotechnology

VeriSIM Life, an AI-driven virtual drug development company based in San Francisco, has acquired Molomics Biotech SL, a Barcelona-based AI-enabled drug discovery firm. The acquisition integrates Molomics' AI + Human Collective Intelligence discovery technology into VeriSIM's BIOiSIM platform to accelerate and improve success rates in drug discovery, including work on Parkinson's disease.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

IMEG Acquires Innovae

October 1, 2024

Engineering Services

IMEG has acquired Innovae, a Colorado-based multi-discipline industrial engineering design firm, expanding IMEG’s capabilities in pharmaceutical, food & beverage and other life-science related manufacturing sectors. Innovae will continue operating from its Centennial and Boulder locations and its president, Dan Weisiger, will remain as the client executive for the team.